GeoVax Labs (GOVX) vs Onconetix (ONCO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Onconetix is the larger company by market cap ($3.4 million vs $2.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GOVX | ONCO |
|---|---|---|
| Share price | $0.2866 | $0.6543 |
| Market cap | $2.90M | $3.43M |
| 1-day change | -0.97% | +9.56% |
| P/E ratio (TTM) | — | 0.00 |
| EPS (TTM) | $-8.84 | $310.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.75 | $207.00 |
| 52-week low | $0.277 | $0.58 |
| Distance from 52-week high | -98.18% | -99.68% |
| Analyst consensus | none | — |
| Avg. price target upside | +3389.18% | — |
| Average volume | 771.47K | 2.96M |
| Shares outstanding | 10.10M | 5.24M |
| Employees | 19 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About GeoVax Labs
GOVX stock →GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
Healthcare · Biotechnology · 19 employees
About Onconetix
ONCO stock →Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
Healthcare · Biotechnology · 2 employees
GOVX vs ONCO FAQ
Which is bigger, GeoVax Labs or Onconetix?
Onconetix (ONCO) is larger, with a market capitalization of $3.43M compared with $2.90M for GeoVax Labs (GOVX).
Are GeoVax Labs and Onconetix in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.